Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18767034 | 1.00 | CA2 (0.47) | CA2ALDH1A1NPSR1TMEM97SIGMAR1 | |
| SCHEMBL899349 | 1.00 | CA2 (0.47) | CA2ALDH1A1NPSR1TMEM97SIGMAR1 | |
| SCHEMBL27613931 | 0.81 | CA2 (0.44) | CA2ALDH1A1NPSR1TMEM97SIGMAR1 | |
| SCHEMBL7152435 | 0.80 | CA2 (0.45) | CA2ALDH1A1NPSR1TMEM97SIGMAR1 | |
| SCHEMBL7156770 | 0.80 | CA2 (0.45) | CA2ALDH1A1NPSR1TMEM97SIGMAR1 | |
| SCHEMBL10027876 | 0.79 | CA2 (0.43) | CA2ALDH1A1NPSR1TMEM97SIGMAR1 | |
| SCHEMBL12400279 | 0.79 | CA2 (0.43) | CA2ALDH1A1NPSR1TMEM97SIGMAR1 | |
| SCHEMBL12399571 | 0.79 | CA2 (0.43) | CA2ALDH1A1NPSR1TMEM97SIGMAR1 | |
| SCHEMBL12976171 | 0.76 | — | — | |
| SCHEMBL13305488 | 0.76 | CA2 (0.41) | CA2ALDH1A1NPSR1TMEM97SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4717316-A2 | ANTI-EGFR ANTIBODY-DRUG CONJUGATES | AbbVie Inc. (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20250213685-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2025-07-03 | — | — | US | disclosed |
| US-20250177374-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC (US) | 2025-06-05 | — | — | US | disclosed |
| US-20250170263-A1 | ANTI-EGFR ANTIBODY-DRUG CONJUGATES | ABBVIE INC (US) | 2025-05-29 | — | — | US | disclosed |
| US-20250171435-A1 | Carbon Linked BCL Inhibitors and Senolytic Compounds and Uses Thereof | Rubedo Life Sciences, Inc. | 2025-05-29 | — | — | US | disclosed |
| EP-4364754-A2 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| US-20240115725-A1 | Anti-EGFR Antibody-Drug Conjugates | ABBVIE INC (US) | 2024-04-11 | — | — | US | disclosed |
| US-20240058450-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC (US) | 2024-02-22 | — | — | US | disclosed |
| EP-4281117-A1 | ANTI-EGFR ANTIBODY-DRUG CONJUGATES | AbbVie Inc. (US) | 2023-11-29 | — | — | EP | disclosed |
| CN-117015404-A | Anti-EGFR antibody drug conjugates | 艾伯维公司 | 2023-11-07 | — | — | CN | disclosed |
| EP-2170060-A1 | alpha-CHLORO AND alpha-BROMO PHOSPHONATE ANALOGS OF LYSOPHOSPHATIDIC ACID AND METHODS OF MAKING AND USING THEREOF | University of Utah Research Foundation (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2008157361-A1 | α-CHLORO AND α-BROMO PHOSPHONATE ANALOGS OF LYSOPHOSPHATIDIC ACID AND METHODS OF MAKING AND USING THEREOF | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20080194654-A1 | HYDROXY-SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-08-14 | — | — | US | disclosed |
| EP-1234885-B1 | A process for the preparation of beta-hydroxy-delta-lactone using novel intermediates | COUNCIL SCIENT IND RES (IN) | 2008-07-23 | — | — | EP | disclosed |
| US-20070123492-A1 | Analogs of lysophosphatidic acid and methods of making and using thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-05-31 | — | — | US | disclosed |
| EP-1234885-A1 | A process for the preparation of beta-hydroxy-delta-lactone using novel intermediates | Council of Scientific & Industrial Research (IN) | 2002-08-28 | — | — | EP | disclosed |
| US-6417374-B1 | Process for the preparation of beta hydroxy-delta lactone using novel intermediates | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2002-07-09 | — | — | US | disclosed |
| EP-0553358-B1 | PROCESS FOR PRODUCING 3-DPA-LACTONE | JAPAN TOBACCO INC (JP) | 1996-11-06 | — | — | EP | disclosed |
| US-5391769-A | Method of preparing 3-DPA-lactone | JAPAN TOBACCO INCORPORATED (JP) | 1995-02-21 | — | — | US | disclosed |
| EP-0553358-A1 | PROCESS FOR PRODUCING 3-DPA-LACTONE | Japan Tobacco Inc. (JP) | 1993-08-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250170263-A1 | ANTI-EGFR ANTIBODY-DRUG CONJUGATES | EGFR, ERBB3, ERBB2 | CA2 2796/4885ALDH1A1 3490/4885NPSR1 2260/4885 |
| US-20250213685-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | CA2 2461/4885ALDH1A1 1891/4885NPSR1 2055/4885 |
| US-20250171435-A1 | Carbon Linked BCL Inhibitors and Senolytic Compounds and Uses Thereof | BCL2, BCL2A1, BCL2L1 | CA2 2083/4885ALDH1A1 1453/4885NPSR1 4673/4885 |
| US-20240115725-A1 | Anti-EGFR Antibody-Drug Conjugates | EGFR, ERBB2, ERBB3 | CA2 2743/4885ALDH1A1 1828/4885NPSR1 3020/4885 |
| US-20250177374-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | BCL2, BAX, BCL9 | CA2 2615/4885ALDH1A1 2826/4885NPSR1 4409/4885 |
| US-20070123492-A1 | Analogs of lysophosphatidic acid and methods of making and using thereof | LPAR4, LPAR2, LPAR5 | CA2 2763/4885ALDH1A1 3349/4885NPSR1 2241/4885 |
| US-20240058450-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | BCL2, BAX, BCL9 | CA2 2615/4885ALDH1A1 2826/4885NPSR1 4409/4885 |
| US-20080194654-A1 | HYDROXY-SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | SLC6A4, SLC6A2, TPH1 | CA2 3497/4885ALDH1A1 566/4885NPSR1 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.